Targeting specific proteins to treat cancer
Bromodomain-selective inhibitors for cancer therapy
['FUNDING_R01'] · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · NIH-10690591
This study is working on new drugs that can specifically target certain proteins involved in cancer, aiming to kill cancer cells while keeping healthy cells safe, which could make cancer treatments more effective and cause fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (nih funded) |
| Locations | 1 site (MEMPHIS, UNITED STATES) |
| Trial ID | NIH-10690591 on ClinicalTrials.gov |
What this research studies
This research focuses on developing selective inhibitors that target specific bromodomains in proteins involved in cancer. By understanding how these proteins interact with chemical marks on DNA, the researchers aim to create drugs that can effectively kill cancer cells while sparing normal cells. The approach involves synthesizing new compounds that selectively inhibit one of the bromodomains, which has shown promise in laboratory models. The goal is to improve the effectiveness of cancer therapies and reduce side effects associated with traditional treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with specific types of cancer that exhibit overexpression of BET proteins.
Not a fit: Patients with cancers that do not involve the BET protein family may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown that targeting bromodomains can be effective in treating certain cancers, indicating a promising avenue for further exploration.
Where this research is happening
MEMPHIS, UNITED STATES
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL — MEMPHIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHELAT, ANANG A — ST. JUDE CHILDREN'S RESEARCH HOSPITAL
- Study coordinator: SHELAT, ANANG A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Saint Jude Children's Cancer Center, St. Jude Children's Cancer Center, St. Jude Children's Research Hospital Comprehensive Cancer Center, St.Jude Children's Cancer Center, St.Jude Children's Research Hospital Comprehensive Cancer Center